Study of the Inhibitory Effect of Antibodies Against C3 Complement Component in a Rat Model of Traumatic Brain Injury

Authors: Gorbunov N..¹, Ischenko A..¹, Zhakhov A..¹, Trofimov A..¹, Denisenko E..¹, Alexandrov G..¹, Zakharov M..¹
Affiliations:
Issue: Vol 21, No 4 (2018)
Pages: 641-643
Section: SHORT COMMUNICATIONS
Submitted: 22.10.2020
Published: 15.10.2018
URL: https://rusimmun.ru/jour/article/view/804
DOI: https://doi.org/10.31857/S102872210002623-0
ID: 804

Cite item

Full Text

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

Email: noemail@neicon.ru
Russian Federation

Email: noemail@neicon.ru
Russian Federation

Email: noemail@neicon.ru
Russian Federation

Email: noemail@neicon.ru
Russian Federation

Email: noemail@neicon.ru
Russian Federation

Email: noemail@neicon.ru
Russian Federation

Brennan F. H., Lee J. D., Ruitenberg M. J., Woodruff T. M. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions // Semin Immunol. 2016. 28(3). P. 292–308.
Alawieh A., Tomlinson S. Injury site-specifi c targeting of complement inhibitors for treating stroke // Immunol. Rev. 2016. Vol. 274 (1). P. 270–280.
Alawieh A., Elvington A., Zhu H., Yu J., Kindy M. S., Atkinson C., Tomlinson S., Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement //J Neuroinfl ammation. 2015. Vol.12. P. 247–259.
Mastellos D. C., Reis E. S., Yancopoulou D., Hajishengallis G., Ricklin D., Lambris J. D. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage // Immunobiology. 2016. Oct. Vol.221(10).P.1046–57.

Supplementary Files

Action

1. JATS XML